DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains

Scott, JK; Gulzar, Naveed; Klaric, Kristina-Ana; Ross, TM; Lu, Shan; Wang, S

doi:10.1186/1742-4690-9-s2-p348

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data showed that 4-1BBL DNA increased the Gag-specific IgG and cellular immune responses. Importantly, the expression of Gag and 4-1BBL from the same plasmid was critical for the adjuvant activity [82].…”

Section: Adjuvantsmentioning

confidence: 99%

“…Indeed, a percentage of these cells transform into antigen-specific memory T cells. In a heterologous boost, because the priming and boosting vectors are different, T cells that specifically target the viral vector are not boosted and do not activate cell number control mechanisms, therefore allowing for greater development of the disease antigen-specific T-cell populations [82]. Several groups have now established that heterologous prime-boost regimens are the most potent strategies to induce cellular immune responses [86,87].…”

Section: Heterologous Prime-boost Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Which Vaccination Strategies and Immune Responses are More Effective Against HIV Infections?

Bolhassani¹

2016

Advances in Molecular Retrovirology

View full text Add to dashboard Cite

Vaccination is one of the most successful approaches for controlling various viral diseases. Novel approaches will be needed to develop highly effective vaccines to prevent infectious diseases such as HIV. There are many aspects of HIV-biology that make the development of an HIV vaccine difficult, including viral diversity, effective type of immune response, and suitable experimental model for preclinical trials. In spite of these challenges, recent published results showed that a vaccine regimen could reduce HIV infection rates by % in Thailand. This vaccine named as RV is composed of a recombinant canarypox vector expressing three HIV-proteins as a prime and two different recombinant HIV-gp envelope glycoproteins with alum adjuvant as a boost. In addition, a subunit vaccine constructed from the viral envelope protein could be efficiently developed using new techniques available through genetic engineering. The current HIV-vaccine development focuses on antibody-based approaches. It was shown that immunization with the viral envelope glycoprotein, gp , should generate neutralizing antibodies that would prevent infection, thereby yielding protective immunity. However, HIV could develop many pathways to escape from antibodies that bind to the different parts of the viral envelope molecules. Thus, the generation of neutralizing antibodies is very difficult after viral infection or immunization protocols. Indeed, the viral envelope molecules Env possess glycosylated residues that cover surface epitopes for binding and neutralizing antibodies, even if the antibodies are produced. Furthermore, the trimeric structures of envelope molecules show rapid conformational changes due to the interaction with viral cell surface receptors, CCR /CXCR and CD thus the transition state is very poor to be recognized by the immune system. Currently, studies focus on generating stable trimeric envelope molecules gp /gp as immunogens that can induce neutralizing antibodies that can compete for binding to the cell surface receptors. "ltogether, it is clear that the design of a vaccine to elicit HIV-neutralizing antibodies is not straightforward, and it causes major challenges in structural biology and immunology, several other studies strongly suggest cytotoxic T-lymphocyte CTL -based immune responses against HIV infections. Indeed, CD +

show abstract

Section: Adjuvantsmentioning

confidence: 99%

Section: Heterologous Prime-boost Strategiesmentioning

confidence: 99%

Which Vaccination Strategies and Immune Responses are More Effective Against HIV Infections?

Bolhassani¹

2016

Advances in Molecular Retrovirology

View full text Add to dashboard Cite

show abstract

“…The HIV-1 gp41 MPER contains the epitopes for broadly neutralizing antibodies (NAbs), making it as a target for HIV vaccine design. The studies indicated that DNA vaccines expressing the MPER of HIV-1 gp41 induce different antibodies depending on their transmembrane and cytoplasmic domains [16]. In addition, neutralizing antibodies, which recognize the main neutralizing determinants of the gp120 Env protein (e.g., the V3 loop region), have been shown to effectively block cell fusion and virus infectivity independent of the initial gp120-CD4 binding [17].…”

Section: Structure and Function Of Dna Vaccinementioning

confidence: 99%

How can Improve DNA Vaccine Modalities as a Therapeutic Approach against HIV Infections?

Habibzadeh¹

2015

J AIDS Clin Res

View full text Add to dashboard Cite

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains

Cited by 2 publications

References 0 publications

Which Vaccination Strategies and Immune Responses are More Effective Against HIV Infections?

Which Vaccination Strategies and Immune Responses are More Effective Against HIV Infections?

How can Improve DNA Vaccine Modalities as a Therapeutic Approach against HIV Infections?

Contact Info

Product

Resources

About